Dergiler / Hitit Medical Journal / 2026 / Cilt: 8 Sayı: 2

İleri Evre Klasik Hodgkin Lenfomada Sağkalımın Öngörülmesinde Prognostik Bir Araç Olarak Endotelyal Aktivasyon ve Stres İndeksi (EASIX)

Endothelial Activation and Stress Index (EASIX) as a Prognostic Tool for Predicting Survival in Advanced-Stage Classical Hodgkin Lymphoma

Murat Kaçmaz(UNIVERSITY OF HEALTH SCIENCES, DİYARBAKIR GAZİ YAŞARGİL HEALTH RESEARCH CENTER, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, HEMATOLOGY)0000-0003-1111-8605
Şengül Baran Yerlikaya(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, DİYARBAKIR GAZİ YAŞARGİL SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, HEMATOLOJİ BİLİM DALI)0000-0001-9624-8091
Cihan Ural(VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ)0000-0003-1209-4668
Ali Dogan(VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ)0000-0003-0207-3505
Cengiz Demir(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, DİYARBAKIR GAZİ YAŞARGİL SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, HEMATOLOJİ BİLİM DALI)0000-0001-9856-184X
Sayfa
386–395
Yayın Tarihi
2026-06-29
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bulgular: Toplam 85 hasta analiz edildi.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:ÖZET Amaç: Endotelyal Aktivasyon ve Stres İndeksi (EASIX) skorunun prognostik önemi, çeşitli hematolojik malignitelerde gösterilmiştir.
📊
Temel Bulgular & Veri:Bu çalışmanın amacı, ileri evre klasik Hodgkin lenfomalı (kHL) hastalarda EASIX skorunun sağkalım sonuçlarını öngörmedeki değerini incelemektir.
💡
Sonuç & Katkı:Bulgular: Toplam 85 hasta analiz edildi.
🔬Tür:Araştırma Makalesi
📍Kapsam:85 hasta
⚙️Değişkenler:Hodgkin Hastalığı · Prognoz · Kreatinin

Özet

ÖZET Amaç: Endotelyal Aktivasyon ve Stres İndeksi (EASIX) skorunun prognostik önemi, çeşitli hematolojik malignitelerde gösterilmiştir. Bu çalışmanın amacı, ileri evre klasik Hodgkin lenfomalı (kHL) hastalarda EASIX skorunun sağkalım sonuçlarını öngörmedeki değerini incelemektir. Gereç ve Yöntem: Bu retrospektif çalışmaya, birinci basamak tedavi olarak ABVD (doksorubisin, bleomisin, vinblastin, dakarbazin) alan ileri evre kHL’lı (evre IIB–IV) hastalar dahil edildi. EASIX skorları tanı anında, şu formül kullanılarak hesaplandı: serum kreatinin (mg/dL) × LDH (U/L)/trombosit sayısı (10⁹/L). Bulgular: Toplam 85 hasta analiz edildi. Medyan yaş 36 yıl olup hastaların %61,2’si erkekti. ROC analizi ile belirlenen optimal eşik değere (0,66) göre 47 hasta (%55) düşük EASIX grubunda, 38 hasta (%45) ise yüksek EASIX grubunda sınıflandırıldı. Progresyonsuz sağkalım (PFS) açısından gruplar arasında anlamlı bir fark saptanmadı (p = 0,405) ve her iki grupta da medyan PFS’ye ulaşılamadı. Benzer şekilde, genel sağkalım (OS) açısından da anlamlı bir fark izlenmedi (p = 0,295). Yüksek EASIX grubunda medyan OS 141,2 ay iken, düşük EASIX grubunda medyan OS’ye ulaşılamadı. Sonuç: EASIX skoru ile ileri evre kHL’lı hastaların sağkalım sonuçları arasında ilişkili bulunmamıştır. Bu hasta grubunda EASIX’in prognostik rolünü netleştirmek için daha geniş hasta serileriyle yapılacak çalışmalara ihtiyaç vardır.

Abstract

Background: The prognostic significance of the Endothelial Activation and Stress Index (EASIX) score has been demonstrated in several hematologic malignancies. This study aimed to evaluate the predictive value of the EASIX score for survival outcomes in patients with advanced-stage classical Hodgkin Lymphoma (cHL). Material and Method: This retrospective study included patients with advanced-stage cHL (stage IIB–IV) who received ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) as first-line therapy. EASIX scores were calculated at diagnosis using the formula: serum creatinine (mg/dL) × LDH (U/L) / platelet count (10^9/L). Results: A total of 85 patients were analyzed. The median age was 36 years, and 61.2% were male. Based on the optimal ROC-derived cutoff value (0.66), 47 patients (55%) were classified into the low-EASIX group and 38 patients (45%) into the high-EASIX group. Progression-free survival (PFS) did not differ significantly between the groups (p = 0.405), and the median PFS was not reached in either group. Similarly, no significant difference in overall survival (OS) was observed (p = 0.295). The median OS for the high-EASIX group was 141.2 months, while it was not reached in the low-EASIX group. Conclusion: The EASIX score was not associated with survival outcomes in patients with advanced-stage cHL. Further studies with larger cohorts are needed to clarify its prognostic role in this setting.

🔖

Bu Makaleye Atıf Yap

Kaçmaz, M., Yerlikaya, Ş. B., Ural, C., Dogan, A., Demir, C. (2026). İleri Evre Klasik Hodgkin Lenfomada Sağkalımın Öngörülmesinde Prognostik Bir Araç Olarak Endotelyal Aktivasyon ve Stres İndeksi (EASIX). Hitit Medical Journal, Cilt: 8 Sayı: 2, 386–395. https://doi.org/10.52827/hititmedj.1846588

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (29)

  1. Ansell SM. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2022;97(11):1478-1488.
  2. Engert A, Raemaekers J. Treatment of early-stage Hodgkin lymphoma. Semin Hematol 2016;53(3):165-170.
  3. von Tresckow B, Moskowitz CH. Treatment of relapsed and refractory Hodgkin Lymphoma. Semin Hematol 2016;53(3):180-185.
  4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339(21):1506-1514.
  5. Diefenbach CS, Li H, Hong F, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 2015;171(4):530-538.
  6. Ganesan P, Dhanushkodi M, Ganesan TS, et al. Prognostic Utility of the IPS 3 Score for Predicting Outcomes in Advanced Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk 2019;19(2):116-122.
  7. Rodday AM, Parsons SK, Upshaw JN, et al. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. J Clin Oncol 2023;41(11):2076-2086.
  8. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107(1):52-59.
  9. Bari A, Marcheselli R, Sacchi S, et al. The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments. Ann Hematol 2020;99(2):277-282.
  10. Corbacioglu S, Carreras E, Ansari M, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant 2018;53(2):138-145.
  11. Dietrich S, Falk CS, Benner A, et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant 2013;19(1):22-27.
  12. Luft T, Dietrich S, Falk C, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011;118(6):1685-1692.
  13. Nassereddine S, Alsubait S, Tabbara I. Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) Following Hematopoietic Stem Cell Transplant: Insights and Therapeutic Advances. Anticancer Res 2018;38(5):2597-2605.
  14. Luft T, Benner A, Jodele S, et al. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol 2017;4(9):e414-e423.
  15. Luft T, Benner A, Terzer T, et al. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2020;55(3):553-561.
  16. Kordelas L, Terzer T, Gooley T, et al. EASIX-1year and late mortality after allogeneic stem cell transplantation. Blood Adv 2023;7(18):5374-5381.
  17. Merz A, Germing U, Kobbe G, et al. EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer J 2019;9(11):85.
  18. Song GY, Jung SH, Kim K, et al. Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. BMC Cancer 2020;20(1):803.
  19. Park S, Go SI, Lee GW. The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma. BMC Cancer 2022;22(1):816.
  20. Ruco LP, Pittiglio M, Dejana E, Baroni CD. Vascular activation in the histopathogenesis of Hodgkin's disease: potential role of endothelial tissue factor in intravascular thrombosis and necrosis. J Pathol 1993;171(2):131-136.
  21. Aldinucci D, Borghese C, Casagrande N. Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It. Int J Mol Sci 2019;20(10):2416.
  22. Linke F, Harenberg M, Nietert MM, et al. Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma. Leukemia 2017;31(2):361-372.
  23. Estrada-Bernal A, Mendoza-Milla C, Ventura-Gallegos JL, et al. NF-kappaB dependent activation of human endothelial cells treated with soluble products derived from human lymphomas. Cancer Lett 2003;191(2):239-248.
  24. Fhu CW, Graham AM, Yap CT, et al. Reed-Sternberg cell-derived lymphotoxin-α activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma. Blood 2014;124(19):2973-2982.
  25. Rueda A, Olmos D, Vicioso L, et al. Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. Leuk Lymphoma 2015;56(5):1286-1294.
  26. Hunutlu FÇ, Öztop H, Gürsoy V, et al. Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy. Diagnostics (Basel) 2025;15(2):185.
  27. Chim CS, Sim J, Tam S, Tse E, Lie AK, Kwong YL. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens. Eur J Haematol 2015;94(4):330-335.
  28. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010;28(33):4976-4984.
  29. Yadav C, Ahmad A, D'Souza B, et al. Serum Lactate Dehydrogenase in Non-Hodgkin's Lymphoma: A Prognostic Indicator. Indian J Clin Biochem 2016;31(2):240-242.